Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature

Avelumab is an anti-PD-L1 (programmed death-ligand 1) immune checkpoint inhibitor (ICIs) and the monoclonal antibody that constitutes a major development in the immunotherapy of cancer. In 2017, The European Medicine Agency (EMA) approved it as an orphan drug for treatment of gastric cancer. Aveluma...

Descripción completa

Detalles Bibliográficos
Autores principales: Aziz, Kashif, Shahbaz, Amir, Umair, Muhammad, Sachmechi, Isaac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Leibniz Research Centre for Working Environment and Human Factors 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046621/
https://www.ncbi.nlm.nih.gov/pubmed/30034316
http://dx.doi.org/10.17179/excli2018-1357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046621/
https://www.ncbi.nlm.nih.gov/pubmed/30034316
http://dx.doi.org/10.17179/excli2018-1357

Ejemplares similares